Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
IF – 2.1 (5-Year IF – 2.0), JCI (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker – 4.3)
Q1 in SJR 2024, SJR score – 0.598
IC – 171.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2020, vol. 29, nr 11, November, p. 1305–1312

doi: 10.17219/acem/126301

Publication type: original article

Language: English

License: Creative Commons Attribution 3.0 Unported (CC BY 3.0)

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Multicenter experiences with levosimendan therapy and its safety in patients with decompensated advanced heart failure

Małgorzata Lelonek1,A,B,C,D,E,F, Iwona Stopczyńska2,B,F, Ewa Korościk3,B,D,F, Ewa Straburzyńska-Migaj3,A,B,C,E,F, Marcin Gruchała2,A,C,E,F

1 Department of Noninvasive Cardiology, Medical University of Lodz, Poland

2 1st Department of Cardiology, Medical University of Gdańsk, Poland

3 1st Department of Cardiology, Poznan University of Medical Sciences, Poland

Abstract

Background. Advanced heart failure (AdvHF) is associated with high morbidity and mortality. Patients with this clinical condition are potential candidates for heart transplantation or mechanical circulatory support. Initially, however, they are usually supported with inotropic drugs. Recent studies have suggested that levosimendan, independently of hemodynamic improvements, may lead to outcome benefits.
Objectives. To present clinical experiences concerning the indications, effectiveness, tolerance, and safety of levosimendan in the real-life therapy of patients with decompensated AdvHF in 3 cardiac centers in Poland.
Material and Methods. This is a prospective, observational, three-center study. Forty-nine patients with AdvHF admitted with decompensation were included (88% men, mean age 58 years, 65% ischemic etiology, left ventricular ejection fraction (LVEF) in median 20%) and followed up for an early (3 months) and prolonged period (1 year) after infusion of levosimendan. Patients were analyzed in relation to death.
Results. Levosimendan therapy was associated with reduced HF symptoms and signs, New York Heart Association (NYHA) class and level of B-type natriuretic peptide (BNP) at discharge. Five patients died during hospitalization, a further 10 during the three-month follow-up and 3 died during the next nine-month follow-up. During the three-month follow-up, 22 patients were re-hospitalized due to HF and in the next nine-month follow-up 8 were re-hospitalized. A multivariate analysis indicated the QRS duration at discharge (hazard ratio (HR) = 1.02; 95% confidence interval (95% CI) = 1.003–1.03; p = 0.018), high-sensitivity C-reactive protein (hsCRP) (HR = 1.01; 95% CI = 1.004–1.02; p = 0.002), and simultaneous dobutamine infusion (HR = 6.54; 95% CI = 1.4–30.5; p = 0.017) were independent risk factors for death in the one-year follow-up. There were no side effects leading to the interruption of the levosimendan infusion.
Conclusion. The use of levosimendan was safe and associated with clinical improvement and reduction in BNP level in AdvHF patients hospitalized due to HF decompensation, although the mortality and re-hospitalization rate during the one-year follow-up remains high.

Key words

prognosis, levosimendan, advanced heart failure

References (28)

  1. Crespo-Leiro MG, Metra M, Lund LH, et al. Advanced heart failure: A position statement of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018;20(11):1505–1535.
  2. Ponikowski P, Voors AA, Anker SD, et al; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–2200.
  3. Seferovic PM, Jankowska E, Coats AJS, et al; Task Force of the HFA Atlas, and the ESC Atlas of Cardiology leadership, developed in collaboration with the National Heart Failure Societies of the ESC member and ESC affiliated member countries. The Heart Failure Association Atlas: Rationale, objectives, and methods. Eur J Heart Fail. 2020;22(4):638–645.
  4. Rame JE. Introduction to topical collection on updates in advanced heart failure. Curr Heart Fail Rep. 2019;16(5):117–118.
  5. Machaj F, Dembowska E, Rosik J, Szostak B, Mazurek-Mochol M, Pawlik A. New therapies for the treatment of heart failure: A summary of recent accomplishments. Clin Risk Manag. 2019;15:147–155.
  6. Pollesello P, Gal TB, Bettex B, et al. Short-term therapies for treatment of acute and advanced heart failure: Why so few drugs available in clinical use, why even fewer in the pipeline? J Clin Med. 2019; 8(11):1834–1853.
  7. Pollesello P, Ovaska M, Kaivola J, et al. Binding of a new Ca2+ sensitizer, levosimendan, to recombinant human cardiac troponin C: A molecular modeling, fluorescence probe, and proton nuclear magnetic resonance study. J Biol Chem. 1994;269(46):28584–28590.
  8. Papp Z, Édes I, Fruhwald S, et al. Levosimendan: Molecular mechanisms and clinical implications. Consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol. 2012;159(2):82–87.
  9. Nieminen MS, Akkila J, Hasenfuss G, et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol. 2000;36(6):1903–1912.
  10. Bouchez S, Fedele F, Giannakoulas, et al. Levosimendan in acute and advanced heart failure: An expert perspective on posology and therapeutic application. Cardiovasc Drugs Ther. 2018;32(6):617–624.
  11. Lunghetti S, Palmerini E, Urselli R, et al. Effects of levosimendan without loading dose on systolic and diastolic function in patients with end-stage heart failure. Cardiol J. 2011;18(5):532–537.
  12. Follath F, Cleland JG, Just H, et al; Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): A randomised double-blind trial. Lancet. 2002;360(9328):196–202.
  13. Landoni G, Biondi-Zoccai G, Greco M, et al. Effects of levosimendan on mortality and hospitalization: A meta-analysis of randomized controlled studies. Crit Care Med. 2012;40(2):634–646.
  14. Mebazaa A, Nieminen MS, Packer M, et al; SURVIVE Investigators. Levosimendan vs dobutamine for patients with acute decompensated heart failure: The SURVIVE Randomized Trial. JAMA. 2007;297(17):1883–1891.
  15. Packer M, Colucci W, Fisher L, et al; REVIVE Heart Failure Study Group; Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail. 2013;1(2):103–111.
  16. Polleselo P, Parissis J, Kivikko M, Harjola VP. Levosimendan meta-analyses: Is there a pattern in the effect on mortality. Int J Cardiol. 2016;209:77–83.
  17. Silvetti S, Nieminen MS. Repeated or intermittent levosimendan treatment in advanced heart failure: An updated meta-analysis. Int J Cardiol. 2016;202:138–143.
  18. Mebazaa A, Nieminen MS, Filippatos GS, et al. Levosimendan vs dobutamine: Outcomes for acute heart failure patients on beta-blockers in SURVIVE. Eur J Heart Fail. 2009;11(3):304–311.
  19. Bergh CH, Andersson B, Dahlström U, et al. Intravenous levosimendan vs dobutamine in acute decompensated heart failure patients on beta-blockers. Eur J Heart Fail. 2010;12(4):404–410.
  20. Harjola VP, Giannakoulas G, von Lewinski D, et al. Use of levosimendan in acute heart failure. Eur Heart J Suppl. 2018;20(Suppl I):I2–I10.
  21. Gong B, Li Z, Yat Wong PC. Levosimendan treatment for heart failure: A systematic review and meta-analysis. J Cardiothorac Vasc Anesth. 2015;29(6):1415–1425.
  22. Lund LH, Jurga J, Edner M, et al. Prevalence, correlates, and prognostic significance of QRS prolongation in heart failure with reduced and preserved ejection fraction. Eur Heart J. 2013;34(7):529–539.
  23. Kashani A, Barold SS. Significance of QRS complex duration in patients with heart failure. J Am Coll Cardiol. 2005;46(12):2183–2192.
  24. Braunschweig F, Linde C, Benson L, Ståhlberg M, Dahlström U, Lund LH. New York Heart Association functional class, QRS duration, and survival in heart failure with reduced ejection fraction: Implications for cardiac resynchronization therapy. Eur J Heart Fail. 2017;19(3):366–376.
  25. Minami Y, Kajimoto K, Sato N, Hagiwara N; ATTEND Study Investigators. Effect of elevated C-reactive protein level at discharge on long-term outcome in patients hospitalized for acute heart failure. Am J Cardiol. 2018;121(8):961–968.
  26. Matsumoto H, Kasai T, Sato A, et al. Association between C-reactive protein levels at hospital admission and long-term mortality in patients with acute decompensated heart failure. Heart Vessels. 2019;34(12):1961–1968.
  27. Agostoni P, Farmakis DT, Garcia-Pinilla JM, et al. Haemodynamic balance in acute and advanced heart failure: An expert perspective on the role of Levosimendan. Card Fail Rev. 2019;5(3):155–161.
  28. Farmakis D, Agastoni P, Baholli L, et al. A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: An expert panel consensus. Int J Cardiol. 2019;297:83–90.
© Wroclaw Medical University